With the world of Pharma Services moving at a faster and more dynamic pace than ever before, North Point is excited to deliver your monthly “dose” of Pharma Services news, transaction updates, valuation trends, industry themes and more. | | | |
IntegriChain, delivering pharma’s comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, and Knipper Health, a leading healthcare solutions company serving the pharmaceutical, biotechnology, and medical device industries, announced a non-exclusive joint initiative to support emerging manufacturers launching new products that need comprehensive 3PL services, order-to-cash, government pricing, and claims adjudication support. “As emerging pharmaceutical companies plan for their first FDA approval and launch, their commercial and market access functions must accelerate from zero to one hundred overnight,” said Jeff Lee, Senior Vice President of Account Management and Sales of IntegriChain. “As they rapidly morph to fully commercial organizations and stand up their contracts and pricing function and distribution logistics, they require high-touch partners like IntegriChain and Knipper. We combine the industry’s largest platform for contracts and pricing services, proven implementation processes, and integrated industry and technology experts with Knipper’s safe, scalable, compliant, and cost-effective services and outstanding service levels to help these innovators ensure their patients have affordable, timely, and sustainable access to therapy.” | |
Veeva Systems (NYSE: VEEV) today announced that ADVANZ PHARMA is standardizing commercial operations on Veeva Commercial Cloud as it expands in new markets across Europe. With a complete suite of Veeva software and data, ADVANZ can drive a unified field strategy across geographies and strengthen field engagement with healthcare professionals (HCPs). “Since more than doubling our sales and medical footprint with our recent acquisition of Intercept, we needed to scale field operations with a single system to increase visibility throughout the customer engagement journey,” said Andy Eeckhout, global head of CRM and digital solutions at ADVANZ. “With Veeva Commercial Cloud, we have a foundation to maximize impact as we move into new markets.” Focused on products within critical care, anti-infectives, endocrinology, oncology, and other rare diseases, the UK-based biopharma is leveraging Veeva CRM Suite and Veeva OpenData to consolidate operations and gain a complete picture of customers throughout the healthcare ecosystem. ADVANZ’s newly merged field teams can coordinate more effective HCP touchpoints across channels and regions driving relevant engagements. | |
Thyme Care, a value-based oncology platform transforming the care experience for people diagnosed with cancer, today announced it is joining CancerX, a public-private partnership to rapidly accelerate the pace of cancer innovation in the U.S., as a founding member. Co-hosted by the Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH), the national campaign unites a set of diverse stakeholders and innovators to unleash the power of digital innovation and create a future that’s free of the burden of cancer. As a founding member, Thyme Care will help set the strategic direction of the initiative and collaborate on ways to achieve the goals of Cancer Moonshot. Cancer Moonshot aims to slash the cancer death rate in half over the next 25 years. Cancer is the second leading cause of death in the United States. However, despite remarkable advancements in longevity, quality of life often plays a back seat role in the treatment paradigm, and many patients continue to face preventable obstacles to receiving proper care. Patients get discharged from the hospital with a 10-page packet filled with medical jargon in English, when their primary language is Spanish. Many cancer patients have difficulty getting transportation to and from their medical appointments and are at an increased risk of visiting the emergency department because of it. The sheer volume of health appointments required for cancer treatments, sometimes as frequent as three or four times a week, force some people to abandon their jobs and forfeit their health insurance. One-quarter see their savings wiped out. Three-quarters have bills in collections, face tax liens and mortgage foreclosure, or experience other financial setbacks. “Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we’re honored to partner with Thyme Care to achieve the ambitious goals of CancerX,” said Smit Patel, associate program director at DiMe. “Through this impressive collaboration, we will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey.” | |
Renalytix (NASDAQ: RNLX) (LSE: RENX), the first company to develop and commercialize an artificial intelligence (AI) powered in-vitro diagnostic for kidney disease, has selected EVERSANA, a global leader in life-science commercialization services, to expand the company’s commercial footprint for KidneyIntelX, a prognostic device for patients with diabetic kidney disease. Using highly reliable, bioprognostic™ methodology, KidneyIntelX yields a simple-to-understand, custom risk score, helping clinicians better predict which adult patients with type 2 diabetes may be at various stages of chronic kidney disease. “We believe that patients deserve the best options every day in their healthcare journey,” said Jim Lang, CEO at EVERSANA. “What Renalytix has created has the potential to impact millions of lives through early-stage preventative care, which will not only make a huge impact on the global healthcare system but most importantly, improve the lives of patients. We could not be more excited to provide our services to support a successful commercialization.” EVERSANA will launch its field deployment and training solutions with Renalytix to primary care providers across key parts of the United States later this summer. These EVERSANA-supported deployments complement Renalytix existing sales efforts in major markets including New York and Illinois where comprehensive insurance coverage is now available for individuals living with diabetes and kidney disease. “The majority of people with type 2 diabetes over the age of 65 have chronic kidney disease,” said James McCullough, CEO of Renalytix. “EVERSANA will help us bring the benefits of KidneyIntelX early prognosis quickly to large populations at greatest risk to help prevent the unnecessary suffering and unsustainable cost of kidney failure and dialysis.” | |
Healthcare data company ConcertAI announced its expanded partnership with Caris Life Sciences, where the companies will jointly create a database to generate insights to advance precision medicine, clinical trial management and therapeutic development. ConcertAI is a real-world data and AI company for healthcare providers and life science companies, while Caris Life Sciences offers whole exome and whole transcriptome sequencing that uses AI modeling in its clinico-genomic database to help researchers comprehend the molecular complexity of diseases. The partners will develop a database – leveraging both companies’ clinical, molecular and multimodal data – to allow academics and biopharma researchers to gain insights for oncology-focused precision medicine, clinical trial management and therapeutic development. “By building novel research assets at population scale, integrated with leading technologies and talent, we can partner with both academic researchers and biopharma innovators to accelerate new insights into the underpinnings of cancer biology, rapidly translate these insights to the clinic, and enable novel clinical development approaches,” Dr. Jeff Elton, CEO of ConcertAI, said in a statement. “Ultimately, the facilitation of broad-based access to data of this depth and scale, beyond most public or private initiatives, will aid all cancer patients, especially those underserved with few current therapeutic options available to them.” | |
|
Petauri™ Acquires The Kinetix Group
Petauri Health’s initial acquisition marks a key milestone in its mission to develop a platform which offers integrated commercialization solutions. Kinetix Group is a strategic advisory, access marketing and medical affairs agency that partners with life sciences companies.
| |
|
TPG and AmerisourceBergen Announce Completion of Acquisition of OneOncology
TPG (NASDAQ: TPG) and AmerisourceBergen Corporation (NYSE: ABC) announced the completion of their previously announced acquisition of OneOncology, a network of leading oncology practices. TPG has acquired a majority interest in OneOncology, and AmerisourceBergen has acquired a minority interest in the company. OneOncology’s affiliated practices, physicians, and management team have also retained a minority interest in the company. The partnership provides OneOncology with additional resources to grow its platform and invest behind clinical, operational, and technical capabilities to continue to deliver high-quality, comprehensive patient care.
| |
*Note: Market data as of June 30, 2023 | |
|
580 California Street, Suite 2000
San Francisco, CA 94104
415.358.3500
| |
|
76 Eighth Avenue, 8th floor
New York, NY 10011
337.474.7753
| | | | |
